These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

46 related articles for article (PubMed ID: 17510002)

  • 1. Weight and blood pressure changes after switching second-generation antipsychotics in a population of veterans with schizophrenia-related disorders.
    Ried LD; McConkey JR; Bengtson MA; Garman PM; Hsu C; Rahnavard F
    J Am Pharm Assoc (2003); 2007; 47(2):156-64. PubMed ID: 17510002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia.
    Garman PM; Ried LD; Bengtson MA; Hsu C; McConkey JR
    J Am Pharm Assoc (2003); 2007; 47(3):373-8. PubMed ID: 17510032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucose dysregulation among veterans living with schizophrenia-related disorders after switching second-generation antipsychotics.
    Ried LD; Brumback B; Bengtson MA; Garman PM; Hsu C; McConkey JR
    J Am Pharm Assoc (2003); 2009; 49(2):223-31. PubMed ID: 19289350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic monitoring in veterans with schizophrenia-related disorders and treated with second-generation antipsychotics: findings from a Veterans Affairs-based population.
    Hsu C; Ried LD; Bengtson MA; Garman PM; McConkey JR; Rahnavard F
    J Am Pharm Assoc (2003); 2008; 48(3):393-400. PubMed ID: 18595825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study.
    Meyer JM; Pandina G; Bossie CA; Turkoz I; Greenspan A
    Clin Ther; 2005 Dec; 27(12):1930-41. PubMed ID: 16507379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weight change after an atypical antipsychotic switch.
    Ried LD; Renner BT; Bengtson MA; Wilcox BM; Acholonu WW
    Ann Pharmacother; 2003 Oct; 37(10):1381-6. PubMed ID: 14519048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.
    Kinon BJ; Basson BR; Gilmore JA; Tollefson GD
    J Clin Psychiatry; 2001 Feb; 62(2):92-100. PubMed ID: 11247108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone.
    Weiden PJ; Daniel DG; Simpson G; Romano SJ
    J Clin Psychopharmacol; 2003 Dec; 23(6):595-600. PubMed ID: 14624190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased cardiovascular risk with second-generation antipsychotic agent switches.
    Ried LD; Renner BT; McConkey JR; Bengtson MA; Lopez LM
    J Am Pharm Assoc (2003); 2006; 46(4):491-8; quiz 499-501. PubMed ID: 16913393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weight gain on antipsychotic medication is associated with sustained use among veterans with schizophrenia.
    Monnelly EP; Fonda J; Gagnon DR; Chittamooru S; Lawler EV
    J Clin Psychopharmacol; 2015 Feb; 35(1):57-62. PubMed ID: 25514067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
    István S; Agoston T; Tamás T; Zoltán J
    Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and pharmacoeconomic evaluation of switch to olanzapine in veterans with schizophrenia or schizoaffective disorder.
    Davis LL; Cates ME; Lowe JS; Ward LC; Johnson JD; Williford RB; Ambrose SM; Thomas BL; Kashner TM
    Psychopharmacol Bull; 2008; 41(1):85-98. PubMed ID: 18362873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved body weight and metabolic outcomes in overweight or obese psychiatric patients switched to amisulpride from other atypical antipsychotics.
    Lin CC; Bai YM; Wang YC; Chen TT; Lai IC; Chen JY; Chen SY; Gau SS; Liou YJ
    J Clin Psychopharmacol; 2009 Dec; 29(6):529-36. PubMed ID: 19910716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine.
    Peuskens J; De Hert M; Mortimer A;
    Int Clin Psychopharmacol; 2007 May; 22(3):145-52. PubMed ID: 17414740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
    Ascher-Svanum H; Stensland M; Zhao Z; Kinon BJ
    BMC Psychiatry; 2005 Jan; 5():3. PubMed ID: 15649317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
    McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH
    J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in neuroendocrine and metabolic hormones induced by atypical antipsychotics in normal-weight patients with schizophrenia.
    Popovic V; Doknic M; Maric N; Pekic S; Damjanovic A; Miljic D; Popovic S; Miljic N; Djurovic M; Jasovic-Gasic M; Dieguez C; Casanueva FF
    Neuroendocrinology; 2007; 85(4):249-56. PubMed ID: 17570902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment persistence: a comparison among patients with schizophrenia who were initiated on atypical antipsychotic agents.
    Ren XS; Qian S; Lee AF; Herz L; Miller DR; Kazis LE
    J Clin Pharm Ther; 2006 Feb; 31(1):57-65. PubMed ID: 16476121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.
    Rosenheck R; Perlick D; Bingham S; Liu-Mares W; Collins J; Warren S; Leslie D; Allan E; Campbell EC; Caroff S; Corwin J; Davis L; Douyon R; Dunn L; Evans D; Frecska E; Grabowski J; Graeber D; Herz L; Kwon K; Lawson W; Mena F; Sheikh J; Smelson D; Smith-Gamble V;
    JAMA; 2003 Nov; 290(20):2693-702. PubMed ID: 14645311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.